Mohamed R. El Tohamy

Dr. Mohamed R. El Tohamy

Biomedical Sciences - CESC Lab, Zewail City of Science and Technology, Cairo, Al Qāhirah, Egypt
orcid
Research Assistant at Center of Excellence for Stem Cells an...

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Drug Development Research
Verified
Journal Article
Open access
MNMohamed S. Nafie
Mohamed S. Nafie
MDMohamed Khaled Diab
Mohamed Khaled Diab
AYAsmaa S. A. Yassen
Asmaa S. A. Yassen
AEAmany M. Elshamy
Amany M. Elshamy
Mohamed R. El TohamyMohamed R. El Tohamy
Mohamed R. El Tohamy
Sherif Ashraf FahmySherif Ashraf Fahmy
Sherif Ashraf Fahmy
Proteolysis‐targeting chimeras (PROTACs)‐mediated protein degradation has been recently developed as a game‐changing approach in oncology drug development. It represents a paradigm shift from traditional enzyme inhibition to selective protein degradation. PROTACs are different from regular small‐molecule inhibitors because they are heterobifunctional compounds that use the ubiquitin‐proteasome system to breakdown disease‐causing oncogenic proteins. This review discusses the next generation of PROTAC platforms that innovate beyond traditional designs, such as dual‐targeting PROTACS that present a novel mode of action, transcription factor‐targeting PROTACs (TF‐PROTACs), phosphorylation‐dependent PROTACs (PhosphoTACs), and phosphorylation binding chimeras (PhosTACs). In kinase degradation, PROTACs have shown promise in addressing resistance mechanisms and carcinogenic drivers. Despite these advancements, issues with clinical pharmacokinetics, E3 ligase tissue selectivity, and subcellular localization persist. Additionally, the development of bio‐responsive and spatially controlled PROTAC systems, such as photocaged and folate‐caged PROTACs, was fully discussed, which achieves maximal precision in tumor selectivity. Furthermore, ARV‐110 and ARV‐471, as two representative PROTACs, have entered clinical trials, suggesting their potentially broader application. Accordingly, this review provides a critical overview of the design rationales, molecular mechanisms of action, therapeutic utilities, and synthetic issues associated with these innovative modalities, focusing on on their translational implication and pharmacokinetic limitations, as well as potential future clinical applications.